Emerging Markets, Acquisitions Prop Up Growth At Sanofi Aventis
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Viehbacher signals more acquisitions and radical changes in R&D as generics begin to bite into key brands including Plavix.